The most important novelty of the 2018 Hypertension Guidelines of the European Society of Cardiology and the European Society of Hypertension (ESC/ESH) (1) is the decision to abandon the step-care treatment approach, i.e., initial monotherapyfollowed by the sequential addition of one, two, or more antihypertensive agents, as the most important treatment strategy to lower elevated blood pressure (BP) and achieve BP control
📌 3 Key Takeaways
🎯
Objective & Hypothesis:The most important novelty of the 2018 Hypertension Guidelines of the European Society of Cardiology and the European Society of Hypertension (ESC/ESH) (1) is the decision to abandon the step-care treatment approach, i.e., initial monotherapyfollowed by the sequential addition of one, two, or more antihypertensive agents, as the most important treatment strategy to lower elevated blood pressure (BP) and achieve BP control
📊
Key Findings & Data:The most important novelty of the 2018 Hypertension Guidelines of the European Society of Cardiology and the European Society of Hypertension (ESC/ESH) (1) is the decision to abandon the step-care treatment approach, i.e., initial monotherapyfollowed by the sequential addition of one, two, or more antihypertensive agents, as the most important treatment strategy to lower elevated blood pressure (BP) and achieve BP control
💡
Conclusion & Impact:The most important novelty of the 2018 Hypertension Guidelines of the European Society of Cardiology and the European Society of Hypertension (ESC/ESH) (1) is the decision to abandon the step-care treatment approach, i.e., initial monotherapyfollowed by the sequential addition of one, two, or more antihypertensive agents, as the most important treatment strategy to lower elevated blood pressure (BP) and achieve BP control
🔬Design:Research Article
📍Scope:2018 Verileri
⚙️Variables:Domain Parameters
Özet
The most important novelty of the 2018 Hypertension Guidelines of the European Society of Cardiology and the European Society of Hypertension (ESC/ESH) (1) is the decision to abandon the step-care treatment approach, i.e., initial monotherapyfollowed by the sequential addition of one, two, or more antihypertensive agents, as the most important treatment strategy to lower elevated blood pressure (BP) and achieve BP control
🔖
Cite This Article
MANCIA, G. (2019). Initial combination treatment in the 2018 ESC/ESH hypertension guidelines. The Anatolian Journal of Cardiology, Cilt: 22 - Sayı: 3, 100–101. https://ajindex.com/articles/366798
Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al.; Authors/Task Force Members:. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens 2018; 36: 1953-2041
Corrao G, Parodi A, Nicotra F, Zambon A, Merlino L, Cesana G, et al. Better compliance to antihypertensive medications reduces cardiovascular risk. J Hypertens 2011; 29: 610-8
Mancia G, Rea F, Cuspidi C, Grassi G, Corrao G. Blood pressure control in hypertension. Pros and cons of available treatment strategies. J Hypertens 2017; 35: 225-33
Chow CK, Teo KK, Rangarajan S, Islam S, Gupta R, Avezum A, et al.; PURE (Prospective Urban Rural Epidemiology) Study investigators. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA 2013; 310: 959-68
Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ. Combination therapy versus monotherapy in reducing blood pressure: metaanalysis on 11,000 participants from 42 trials. Am J Med 2009; 122: 290-300
Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M, et al.; Task Force Members. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31: 1281-357
Mancia G, Zambon A, Soranna D, Merlino L, Corrao G. Factors involved in the discontinuation of antihypertensive drug therapy: an analysis from real life data. J Hypertens 2014; 32: 1708-15
Mancia G, Rea F, Corrao G, Grassi G. Two-Drug Combinations as First-Step Antihypertensive Treatment. Circ Res 2019; 124: 1113-23
Egan BM, Bandyopadhyay D, Shaftman SR, Wagner CS, Zhao Y, YuIsenberg KS. Initial monotherapy and combination therapy and hypertension control the first year. Hypertension 2012; 59: 1124-31
Gradman AH, Parisé H, Lefebvre P, Falvey H, Lafeuille MH, Duh MS. Initial combination therapy reduces the risk of cardiovascular events in hypertensive patients: a matched cohort study. Hypertension 2013; 61: 309-18
Claxton AJ, Cramer J, Pierce C. A systematic review of the associati